Discovery & the sleep-factor story

• How DSIP was discovered and why it was called a "sleep factor"
• The sleep science you need to read its studies critically
• Why its mechanism and even its receptor remain unresolved
• How to separate small historical human data from animal-only claims

1. 01 Discovery & the sleep-factor story The peptide that was named for sleep before anyone could prove it free
2. 02 Sleep science foundations The sleep science you need to read DSIP studies honestly paid
3. 03 Chemistry & stability A simple peptide with a serious durability problem paid
4. 04 How DSIP works Many proposed mechanisms, no confirmed target paid
5. 05 The human sleep evidence What the actual human sleep studies show, and how small they are paid
6. 06 Stress, endocrine & the HPA axis DSIP’s clearest human signal is not about sleep at all paid
7. 07 Beyond sleep: other applications Withdrawal, pain, antioxidants, and the lifespan claim paid
8. 08 DSIP in context & regulatory status How DSIP compares to real sleep medicines, and why it never became one paid
9. 09 Dosing & Administration How DSIP is prepared and discussed, for education only paid
10. 10 Safety & Side Effects What we know about DSIP safety, and the bigger gray-market risk paid
11. 11 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam

DSIP came out of a strikingly direct idea: if sleep is driven by a chemical signal, you should be able to take it from a sleeping animal and find it. Monnier and Schoenenberger electrically stimulated the sleep-promoting region of rabbit brains, collected the venous blood, and isolated the fraction that enhanced delta-wave activity when infused into the brain ventricles of other rabbits. Seven years of work, from 1970 to 1977, narrowed it to a single nonapeptide.

DSIP research did not build steadily toward a drug. Its literature grew fast after the isolation: a 1986 update noted how much had accumulated in only two years, including work on insomnia, pain and withdrawal, and a 1984 review already listed effects on hormone levels, circadian patterns and drug withdrawal as well as sleep. The idea at its centre never firmed up, and a 2006 review calls DSIP as a sleep factor extremely poorly documented and still weak. Tracing the timeline shows how a promising "sleep factor" became a long-running scientific puzzle rather than a medicine.

What stands out is the gap between attention and resolution. The literature explored DSIP across sleep, pain, withdrawal and hormones, yet the most basic questions were never answered: no DSIP gene, protein or receptor has been isolated, and in the 2006 review’s words its natural occurrence and biological activity still remain obscure. By then the peptide was being openly called an unresolved riddle.

Strip away the "sleep factor" framing and DSIP is a short, simple chain: nine amino acids in the fixed order Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, often written WAGGDASGE. FDA gives its molecular formula as C35H48N10O15: carbon, hydrogen, nitrogen and oxygen, and no metal. Click each residue below to see what little we can say about its role.

That simplicity is exactly why DSIP is puzzling. There is no confirmed receptor, and a long-running argument about how much of what assays detect is intact DSIP at all. A 1984 paper conceded in its opening line that no definitive evidence for the free peptide had been presented, noted that only a small part of the immunoreactivity was probably the free nonapeptide, and then reported a peak of DSIP-like immunoreactivity in plasma that eluted at the same position as synthetic DSIP. The 2006 review goes further and proposes that a different, DSIP-like peptide accounts for at least part of the signal, so what stays unsettled is where it comes from and what it does. DSIP is also broken down quickly in blood, which sets up the stability problems covered later in the course.

Before the deeper science, here is the honest picture: what is genuinely supported for DSIP versus what is merely interesting. Almost everything sits lower on this scale than the marketing suggests, and keeping the tiers separate is the single most useful skill this course teaches. The four tiers below run from what is genuinely settled down to what is missing entirely, and the gap between them is the whole point. Read the tier, not just the headline, and most overconfident DSIP claims quietly fall a level or two.

DSIP is sold and discussed online with confident claims. Held against the actual studies, most are not flatly false so much as wildly overstated: a small or animal-only signal rounded up into a guarantee. Tap each claim to see its real evidence tier.

The pattern repeats throughout DSIP’s literature: a real but narrow finding, usually in animals or a tiny human sample, gets stretched into a broad health claim. Learning to ask "in what species, how many subjects, measuring what?" is what separates honest reading from hype.

The most interesting idea in DSIP research is that it may not be a sedative at all. Classic sleeping pills force sedation; DSIP appeared, in some studies, to normalise disturbed sleep without knocking subjects out, and even increased daytime sleep pressure after a morning dose. The word normalisation is the investigators’ own: their 1983 multi-study paper reports that a complete normalization of disturbed sleep was achieved by four consecutive injections to insomniacs. The two framings make very different predictions.

This distinction matters for the whole course. The investigators who used the word reported normalisation in insomniacs, people whose sleep was already disturbed. If DSIP is a normaliser rather than a sedative, an effect would be expected mainly in sleepers like them and little in healthy ones, so studies of different sleepers could disagree. That is a prediction, not a finding, and the evidence unit checks it against the small human studies.